Table 1.
Baseline Demographic and Clinical Characteristics
| Variable | Placebo (n=294) | Verapamil (n=297) |
|---|---|---|
| Age, mean±SD y | 62.5±10.8 | 61.8±10.5 |
| Female, % | 35.4 | 37.4 |
| BMI, median (IQR) kg/m2 | 27.9 (25.2 to 31.3) | 28.7 (25.5 to 32.1) |
| Hypertension, % | 84.0 | 79.5 |
| Diabetes mellitus, % | 25.9 | 31.6 |
| Verified dyslipidemia, % | 38.4 | 38.4 |
| Current smoker, % | 32.6 | 31.2 |
| PAD, % | 5.4 | 8.8 |
| CVD, % | 13.6 | 11.8 |
| CHF, % | 8.5 | 5.1 |
| CRF, % | 2.0 | 2.7 |
| Previous MI, % | 22.4 | 29.3 |
| Previous PCI, % | 25.2 | 25.6 |
| Previous CABG, % | 4.4 | 6.1 |
| Concomitant CCB use, % | 19.4 | 26.3 |
| Concomitant BB use, % | 68.4 | 71.7 |
| Concomitant CCB+BB use, % | 14.3 | 19.9 |
| Concomitant NG use, % | 32.0 | 32.0 |
| Concomitant ACEI use, % | 54.1 | 52.2 |
| Concomitant ARB use, % | 21.8 | 23.6 |
BMI indicates body mass index; PAD, peripheral artery disease; CVD, cerebrovascular disease; CHF, congestive heart failure; CRF, chronic renal failure; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; CCB, calcium channel blocker; BB, β‐blocker; NG, nitroglycerin; ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker.